Business Description
Myriad Genetics Inc
NAICS : 325413
SIC : 2835
ISIN : US62855J1043
Share Class Description:
FRA:MYD: Ordinary SharesTotal Employee Number:
2,700Description
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.59 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.63 | |||||
Debt-to-EBITDA | -0.63 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.83 | |||||
Beneish M-Score | -3.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.9 | |||||
3-Year EBITDA Growth Rate | -50.4 | |||||
3-Year FCF Growth Rate | 47.3 | |||||
3-Year Book Growth Rate | -28.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 79.28 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.46 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 10.86 | |||||
9-Day RSI | 25.16 | |||||
14-Day RSI | 36.44 | |||||
3-1 Month Momentum % | 27.7 | |||||
6-1 Month Momentum % | 11.1 | |||||
12-1 Month Momentum % | 44.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.4 | |||||
Quick Ratio | 2.19 | |||||
Cash Ratio | 0.96 | |||||
Days Inventory | 43.13 | |||||
Days Sales Outstanding | 54.11 | |||||
Days Payable | 44.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -10.05 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.96 | |||||
Operating Margin % | -7.73 | |||||
Net Margin % | -48.24 | |||||
EBITDA Margin % | -40.31 | |||||
FCF Margin % | -1.41 | |||||
OCF Margin % | 0.9 | |||||
ROE % | -92.09 | |||||
ROA % | -52.73 | |||||
ROIC % | -11.49 | |||||
3-Year ROIIC % | -6.87 | |||||
ROC (Joel Greenblatt) % | -170.22 | |||||
ROCE % | -63.72 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 119.98 | |||||
PS Ratio | 0.6 | |||||
PB Ratio | 1.5 | |||||
Price-to-Tangible-Book | 3.52 | |||||
Price-to-Operating-Cash-Flow | 214.8 | |||||
EV-to-EBIT | -1.54 | |||||
EV-to-Forward-EBIT | 71.72 | |||||
EV-to-EBITDA | -1.78 | |||||
EV-to-Forward-EBITDA | 14.83 | |||||
EV-to-Revenue | 0.72 | |||||
EV-to-Forward-Revenue | 0.58 | |||||
EV-to-FCF | -25.62 | |||||
Price-to-GF-Value | 0.35 | |||||
Price-to-Median-PS-Value | 0.25 | |||||
Earnings Yield (Greenblatt) % | -64.94 | |||||
FCF Yield % | -4.57 | |||||
Forward Rate of Return (Yacktman) % | 10.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Myriad Genetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 693.299 | ||
| EPS (TTM) (€) | -1.025 | ||
| Beta | 1.0057 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.63 | ||
| Volatility % | 79.48 | ||
| 14-Day RSI | 36.44 | ||
| 14-Day ATR (€) | 0.132756 | ||
| 20-Day SMA (€) | 5.0285 | ||
| 12-1 Month Momentum % | 44.11 | ||
| 52-Week Range (€) | 2.998 - 7.1 | ||
| Shares Outstanding (Mil) | 94.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Myriad Genetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Myriad Genetics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 96 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 95 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | 4.58 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 4.58 (+0.00%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 08:40 | 3.77 (+0.00%) | ||
| General meeting for 2026 | 2026-06-04 08:00 | 3.67 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 4.02 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 4.02 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 21:00 | 4.22 (+0.00%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 13:40 | 4.38 (+0.00%) |
Show
Entries
Myriad Genetics Inc Frequently Asked Questions
What is Myriad Genetics Inc(FRA:MYD)'s stock price today?
The current price of FRA:MYD is €4.33. The 52 week high of FRA:MYD is €7.10 and 52 week low is €3.00.
When is next earnings date of Myriad Genetics Inc(FRA:MYD)?
The next earnings date of Myriad Genetics Inc(FRA:MYD) is 2026-11-03 Est..
Does Myriad Genetics Inc(FRA:MYD) pay dividends? If so, how much?
Myriad Genetics Inc(FRA:MYD) does not pay dividend.
Press Release
Articles on Myriad Genetics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers